Molecules that inhibit the synthesis of the ataxin 2 protein can ameliorate the effects of two neurodegenerative diseases in mouse models, raising hopes for the success of this approach in clinical trials. See Letters p.362 & p.367
This is a preview of subscription content, log in via an institution to check access.
Notes
References
Scoles, D. R. et al. Nature 544, 362–366 (2017).
Becker, L. A. et al. Nature 544, 367–371 (2017).
Pulst, S.-M. et al. Nature Genet. 14, 269–276 (1996).
Elden, A. C. et al. Nature 466, 1069–1075 (2010).
Sephton, C. F. et al. J. Biol. Chem. 285, 6826–6834 (2010).
Kiehl, T.-R. et al. Biochem. Biophys. Res. Commun. 339, 17–24 (2006).
Ramaswami, M., Taylor, J. P. & Parker, R. Cell 154, 727–736 (2013).
Finkel, R. S. et al. Lancet 388, 3017–3026 (2016).
Hua, Y. et al. Nature 478, 123–126 (2011).
DeVos, S. L. & Miller, T. M. Neurotherapeutics 10, 486–497 (2013).
Author information
Authors and Affiliations
Corresponding authors
Related links
Rights and permissions
About this article
Cite this article
Zhang, K., Rothstein, J. Two–for–one on potential therapies. Nature 544, 302–303 (2017). https://doi.org/10.1038/nature21911
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature21911
- Springer Nature Limited
This article is cited by
-
Current Status of Antisense Oligonucleotide-Based Therapy in Neuromuscular Disorders
Drugs (2020)
-
Inhibition of Cyclooxygenase-2 (COX-2) Initiates Autophagy and Potentiates MPTP-Induced Autophagic Cell Death of Human Neuroblastoma Cells, SH-SY5Y: an Inside in the Pathology of Parkinson’s Disease
Molecular Neurobiology (2018)